Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch

You may also be interested in...



Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch

Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.

Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch

Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.

Somaxon Sees “Clear Path” For Silenor Sleep Aid Switch

Somaxon Pharmaceuticals expects to make Silenor sleep aid available OTC in five to seven years.

Related Content

Topics

UsernamePublicRestriction

Register

PS104458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel